Neuroendocrine Carcinoma
Showing 26 - 50 of 8,789
Advanced Malignant Solid Tumor, Anal Carcinoma, Biliary Tract Carcinoma Trial in Jacksonville (Clinical Encounter, Home Health
Not yet recruiting
- Advanced Malignant Solid Neoplasm
- +18 more
- Clinical Encounter
- +3 more
-
Jacksonville, FloridaMayo Clinic in Florida
Jul 24, 2023
Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung Trial (LB2102)
Not yet recruiting
- Small Cell Lung Cancer Extensive Stage
- Large Cell Neuroendocrine Carcinoma of the Lung
- LB2102
- (no location specified)
Jan 10, 2023
Large-Cell Neuroendocrine Carcinoma Trial in Lexington (Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma,
Recruiting
- Large-Cell Neuroendocrine Carcinoma
- Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma
- Treatment for Small Cell Lung Cancer
-
Lexington, KentuckyMarkey Cancer Center, University of Kentucky
Jan 12, 2022
Small-cell Lung Cancer, Neuroendocrine Carcinoma Trial (Iadademstat, Paclitaxel)
Not yet recruiting
- Small-cell Lung Cancer
- Neuroendocrine Carcinoma
- (no location specified)
Jun 13, 2022
Neuroendocrine Neoplasms Including Adrenocortical Carcinoma
Recruiting
- Neuroendocrine Tumors
- Carcinoma, Neuroendocrine
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma, Medullary Thyroid Carcinoma Trial (Lu-177 DOTATATE
Not yet recruiting
- Bronchial and Thymic Neuroendocrine Tumour
- +3 more
- Lu-177 DOTATATE (Lutathera®)
- (no location specified)
Nov 1, 2023
Anal Squamous Cell Carcinoma, Colorectal Tumors, Soft Tissue Sarcoma Trial (Regorafenib in combination with Tislelizumab)
Not yet recruiting
- Anal Squamous Cell Carcinoma
- +7 more
- Regorafenib in combination with Tislelizumab
- (no location specified)
Oct 12, 2022
Carcinoma, Cervix Carcinoma Trial in Fuzhou (Karelizumab combined with etoposide and cisplatin)
Not yet recruiting
- Carcinoma
- Cervix Carcinoma
- Karelizumab combined with etoposide and cisplatin
-
Fuzhou, Fujian, ChinaFujian Cancer Hospital
Jun 9, 2023
Neuroendocrine Tumors, Neuroendocrine Carcinoma Trial in Beijing, Xiamen, Harbin (Chidamide, Etoposide + Cisplatin/Carboplatin)
Recruiting
- Neuroendocrine Tumors
- Neuroendocrine Carcinoma
- Chidamide
- Etoposide + Cisplatin/Carboplatin
-
Beijing, Beijing, China
- +2 more
Nov 2, 2021
Neuroendocrine Carcinoma of Pancreas, Duodenum Carcinoma, Pancreas Tumor Trial in Amsterdam, Rotterdam (Stereotactic
Recruiting
- Neuroendocrine Carcinoma of Pancreas
- +6 more
- Stereotactic radiotherapy
-
Amsterdam, North-Holland, Netherlands
- +1 more
Nov 29, 2022
Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma Trial in San Francisco (Apalutamide, Cetrelimab)
Recruiting
- Small Cell Neuroendocrine Carcinoma
- +2 more
- Apalutamide
- Cetrelimab
-
San Francisco, CaliforniaUniversity of California, San Francisco
Mar 21, 2022
Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma Trial (Lutetium Lu 177 Dotatate,
Not yet recruiting
- Metastatic Pancreatic Neuroendocrine Tumor
- Unresectable Pancreatic Neuroendocrine Carcinoma
- Lutetium Lu 177 Dotatate
- +4 more
- (no location specified)
Feb 10, 2022
Neuroendocrine Tumors, Neuroendocrine Carcinoma, Pancreas Tumor Trial in Roma, Rome (EUS guided radiofrequency ablation)
Recruiting
- Neuroendocrine Tumors
- +3 more
- EUS guided radiofrequency ablation
-
Roma, RM, Italy
- +1 more
Feb 10, 2022
Neuroendocrine Carcinoma Trial in France (Nivolumab, Ipilimumab)
Active, not recruiting
- Neuroendocrine Carcinoma
-
Aix-en-Provence, France
- +6 more
Mar 9, 2022
Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder Trial in United States (Ipilimumab, Nivolumab)
Recruiting
- Genitourinary Cancer
- +7 more
-
La Jolla, California
- +5 more
Jul 5, 2022
Neuroendocrine Tumors, Neuroendocrine Carcinoma Trial in Germany (Cabozantinib)
Recruiting
- Neuroendocrine Tumors
- Neuroendocrine Carcinoma
-
Göttingen, Lower Saxony, Germany
- +5 more
Jun 27, 2022
Small Cell Lung Carcinoma (SCLC), Neuroendocrine Tumors Trial (BI 764532, Ezabenlimab)
Not yet recruiting
- Small Cell Lung Carcinoma (SCLC)
- Neuroendocrine Neoplasms
- BI 764532
- Ezabenlimab
- (no location specified)
May 25, 2023
Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma Trial in Rochester (VSV-IFNß-NIS, Pembrolizumab)
Recruiting
- Solid Tumor
- +2 more
- VSV-IFNβ-NIS
- Pembrolizumab
-
Rochester, MinnesotaMayo Clinic
Sep 26, 2022
Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder Trial in Washington, Baltimore
Recruiting
- Small Cell Neuroendocrine Carcinoma of Bladder
- +2 more
- Atezolizumab
- +4 more
-
Washington, District of Columbia
- +1 more
Jun 27, 2022
Small Cell Lung Carcinoma, Neuroendocrine Tumors Trial (BI 764532)
Not yet recruiting
- Small Cell Lung Carcinoma
- Neuroendocrine Neoplasms
- BI 764532
- (no location specified)
May 22, 2023
EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine Trial run by the National Cancer Institute (NCI)
Recruiting
- EGFR-Mutated Non-Small-Cell Lung Carcinoma
- Small Cell/Neuroendocrine
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma Trial in United Kingdom, United States (PEN-221)
Completed
- Neuroendocrine Tumors
- +2 more
-
Fort Myers, Florida
- +12 more
Nov 16, 2021
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen
Recruiting
- Castration-Resistant Prostate Carcinoma
- +7 more
- Biopsy
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022
Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma Trial in Xiamen, Harbin (Chidamide, Sintilimab)
Recruiting
- Neuroendocrine Tumors
- +3 more
-
Xiamen, Fujian, China
- +1 more
Nov 22, 2021